IGC (IGC Pharma Inc) Owah-owahan bathi resik saben saham ing taun lumaku

IGC Pharma, Inc. (IGC) is implementing AI and automation to model Alzheimer's treatments, eliminating manual labor. A comparison of EPS with the same period last year demonstrates profitability dynamics, where the current figure is -100.30. The company is scaling its line of cannabinoid drugs to combat dementia. The synergy of natural components and classical medicine creates a unique therapy with no direct market equivalents.
Rincian metrik keuangan lan pasar IGC Pharma Inc (IGC)

Outsourcing drug synthesis to CDMO plants minimizes capital expenditures on equipment for IGC Pharma, Inc. (IGC). This model directly impacts net income, forming the basis for calculating earnings per share (EPS) growth rates. This metric captures the percentage deviation of the current annual EPS from the previous period's figure. It reveals the company's sensitivity to operating expenses and the cost of borrowed capital. By analyzing the magnitude of the annual EPS change, an investor can detect the fundamental degradation of the asset in a timely manner.